Posted in | News | Imaging

Leica Unveils SCN400 2.2 Scanning Platform for Digital Pathology

Leica Microsystems has launched the SCN400 2.2 scanning platform which features batch processing in brightfield as well as multi-channel fluorescence, integrated with convenient workflows, and therefore serves to be a high efficiency solution for digital pathology scanning.

The SCN400 2.2 includes up to five fluorescence channels per slide, thereby delivering a versatile whole slide scanning solution. Having clear focus and channel separation, Leica’s SCN400 2.2 enables clear capturing of multiple markers on a single sample, through which researchers can obtain results from exceptional or rare samples. As this novel platform can hold multiple filter cubes, up to seven distinct fluorescence channels can be effectively used throughout a scanning batch, thereby promoting flexible scanning of various kinds of samples in pharmaceutical and research labs.

The SCN400 2.2 has been designed to achieve compliance with the requirements of brightfield as well as fluorescence imaging in a single scanning platform. Individual fluorophores with similar wavelengths can be precisely separated using monochrome detectors for fluorescence, while color detectors for brightfield ensure exceptional digital slide capture quality.

The advanced tissue finding system in brightfield imaging facilitates automatic detection of the areas for capture. Leica’s patented Dynamic Focus ensures rapid scanning of high resolution whole slide images, by eliminating the slide pre-mapping’s overhead. The SCN400 2.2 has been equipped with the SL801 autoloader that can accommodate 384 slides and therefore serves to be an automated high-throughput system.

Leica’s Total Digital Pathology ensures complete end-to-end solutions for scanning, analysis and optimization of digital pathology images. The SCN400 2.2 is a major part of Leica’s product line contributing to unequaled flexibility and performance. This novel platform will promote slide scanning to be an integrated, simple step in the pathology workflow.

Will Soutter

Written by

Will Soutter

Will has a B.Sc. in Chemistry from the University of Durham, and a M.Sc. in Green Chemistry from the University of York. Naturally, Will is our resident Chemistry expert but, a love of science and the internet makes Will the all-rounder of the team. In his spare time Will likes to play the drums, cook and brew cider.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Leica Microsystems GmbH. (2019, February 27). Leica Unveils SCN400 2.2 Scanning Platform for Digital Pathology. AZoOptics. Retrieved on November 21, 2024 from https://www.azooptics.com/News.aspx?newsID=15900.

  • MLA

    Leica Microsystems GmbH. "Leica Unveils SCN400 2.2 Scanning Platform for Digital Pathology". AZoOptics. 21 November 2024. <https://www.azooptics.com/News.aspx?newsID=15900>.

  • Chicago

    Leica Microsystems GmbH. "Leica Unveils SCN400 2.2 Scanning Platform for Digital Pathology". AZoOptics. https://www.azooptics.com/News.aspx?newsID=15900. (accessed November 21, 2024).

  • Harvard

    Leica Microsystems GmbH. 2019. Leica Unveils SCN400 2.2 Scanning Platform for Digital Pathology. AZoOptics, viewed 21 November 2024, https://www.azooptics.com/News.aspx?newsID=15900.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.